Future Medicinal ChemistryVol. 3, No. 13 OpinionThe paradox of respiratory R&D, and why ‘inhaled-by-design’ heralds a new dawn in asthma and chronic obstructive pulmonary disease treatmentsMike YeadonMike YeadonYeadon Consulting Wickhambreaux, Kent, CT3 1RT, UK. Search for more papers by this authorEmail the corresponding author at yeadon_m@yahoo.co.ukPublished Online:23 Sep 2011https://doi.org/10.4155/fmc.11.97AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: anti-infammatoryasthmaCOPDinhaled-by-designrespiratoryBibliography1 Bousquet J, Mantzouranis E, Cruz AA et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the WHO consultation on severe asthma. J. Allergy Clin. Immunol.126,926–938 (2010).Crossref, Medline, Google Scholar2 Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of COPD – GOLD executive summary. Am. J. Resp. Crit. Care Med.176,532–555 (2007).Crossref, Medline, Google Scholar3 Glossop PA. Discovery of PF-610355: an inhaled once-daily β-2 adrenoceptor agonist for asthma and COPD. Presented at: 240th ACS National Meeting. Boston, MA, USA 22–26 August 2010.Google Scholar4 Solis-Cohen S. The use of adrenal substances in the treatment of asthma. JAMA34,1164–1169 (1900).Crossref, Google Scholar5 Brown HM, Storey G, George WH. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br. Med. J.1,585–590 (1972).Crossref, Medline, CAS, Google Scholar6 Bel EH. Editorial – smoking: a neglected cause of glucocorticoid resistance in asthma. Am. J. Resp. Crit. Care Med.168,1265–1266 (2003).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited ByFormulation of Dry Powders for Inhalation Comprising High Doses of a Poorly Soluble Hydrophobic Drug15 March 2022 | Frontiers in Drug Delivery, Vol. 2Spray-Dried PulmoSphere™ Formulations for Inhalation Comprising Crystalline Drug Particles7 February 2019 | AAPS PharmSciTech, Vol. 20, No. 3Enhanced design of inhaled therapeutics: what does the future hold?Jeffry G Weers19 February 2016 | Therapeutic Delivery, Vol. 7, No. 3Formulation Design of Dry Powders for InhalationJournal of Pharmaceutical Sciences, Vol. 104, No. 10Foamy macrophage responses in the rat lung following exposure to inhaled pharmaceuticals: a simple, pragmatic approach for inhaled drug development6 November 2013 | Journal of Applied Toxicology, Vol. 34, No. 4Nonhuman targets in allergic lung conditionsClive Robinson, Jihui Zhang, Gary K Newton & Trevor R Perrior30 January 2013 | Future Medicinal Chemistry, Vol. 5, No. 2Inhalation by designLyn H Jones & Adam D Hughes23 September 2011 | Future Medicinal Chemistry, Vol. 3, No. 13 Vol. 3, No. 13 Follow us on social media for the latest updates Metrics Downloaded 338 times History Published online 23 September 2011 Published in print October 2011 Information© Future Science LtdKeywordsanti-infammatoryasthmaCOPDinhaled-by-designrespiratoryFinancial & competing interests disclosure‘The author was an employee of Pfizer at the time of writing. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.PDF download